Singapore’s S*BIO Finds Ideal Partner In CTI For Its JAK2 Inhibitor Abandoned By Onyx
This article was originally published in PharmAsia News
Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.
You may also be interested in...
Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.
Incyte Corp. hits the trifecta – a first-in-class, first-in-disease and first launch with the Nov. 16 FDA approval of Jakafi (ruxolitinib) for treatment of the progressive bone marrow cancer.
Although anxious to move forward into Phase III trials, Singapore-based S*BIO announced May 4 that partner Onyx Pharmaceuticals will not exercise its options to develop S*BIO's JAK2 inhibitors SB1518 and SB1578. The Singapore biotech has regained full rights to the janus kinase inhibitors and will now look for a new partner to help move forward in development